alexa Targeted Therapies in Melanoma: Knowledge, Resistance and Perspectives

ISSN: 2157-2518

Journal of Carcinogenesis & Mutagenesis

  • Review Article   
  • J Carcinog Mutagen 2014, Vol 0(0)
  • DOI: 10.4172/2157-2518.S4-004

Targeted Therapies in Melanoma: Knowledge, Resistance and Perspectives

*Corresponding Author:

Received Date: Nov 30, -0001 / Accepted Date: Nov 30, -0001 / Published Date: May 31, 2014


Several molecular mechanism appear to play a major role in melanoma genesis and progression. Current targeted therapies focus on contrasting the activation of RAS/RAF/MEK/ERK and, to a less extent, PI3K/AKT pathways. Development of inhibitors of key effectors (mainly, BRAF mutant and MEK) has significantly improved treatment of patients with advanced melanoma. However, only rarely tumours present a durable regression due to a large variety of acquired and intrinsic mechanisms that drive resistance to the main targeted inhibitors. All these evidence suggest that in melanoma, as probably in all types of cancer, use of a combinatorial treatment approach, instead of targeting a single component of melanomagenesis pathways, could delay or prevent the emergence of resistance mechanisms responsible to tumour relapse. In this sense, a crucial step is thus represented by the full knowledge of such molecular mechanisms.

Keywords: Melanoma, MAPK pathway, Targeted therapy, Drug resistance

Select your language of interest to view the total content in your interested language

Post Your Comment
Share This Article
Article Usage
  • Total views: 11930
  • [From(publication date): 0-2014 - Dec 13, 2017]
  • Breakdown by view type
  • HTML page views: 8121
  • PDF downloads: 3809